R152
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- MYC_TARGETS_V1+0.480
- G2M_CHECKPOINT+0.470
- PROTEIN_SECRETION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.400
- MTORC1_SIGNALING+0.290
- DNA_REPAIR+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- MITOTIC_SPINDLE+0.220
- INTERFERON_ALPHA_RESPONSE+0.210
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.340
- APICAL_SURFACE-0.310
- ESTROGEN_RESPONSE_EARLY-0.290
- PANCREAS_BETA_CELLS-0.280
- BILE_ACID_METABOLISM-0.250
- ESTROGEN_RESPONSE_LATE-0.240
- KRAS_SIGNALING_DN-0.230
- XENOBIOTIC_METABOLISM-0.230
- PEROXISOME-0.220
- MYOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-G2-A2EF-01A-12R-A18C-07 | — | — | 0.844 |
| 2 | SRR934892 | — | — | 0.815 |
| 3 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.807 |
| 4 | SRR934912 | — | — | 0.805 |
| 5 | SRR934902 | — | — | 0.801 |
| 6 | SRR934878 | — | — | 0.799 |
| 7 | MNG1067 | — | — | 0.794 |
| 8 | SRR934804 | — | — | 0.793 |
| 9 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.791 |
| 10 | SRR934930 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |